AR083575A1 - Aminopirazoles para inhibir la proteinquinasa chk1 - Google Patents

Aminopirazoles para inhibir la proteinquinasa chk1

Info

Publication number
AR083575A1
AR083575A1 ARP110103973A ARP110103973A AR083575A1 AR 083575 A1 AR083575 A1 AR 083575A1 AR P110103973 A ARP110103973 A AR P110103973A AR P110103973 A ARP110103973 A AR P110103973A AR 083575 A1 AR083575 A1 AR 083575A1
Authority
AR
Argentina
Prior art keywords
proteinquinase
aminopirazols
chk1
inhibit
hemioxalate
Prior art date
Application number
ARP110103973A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR083575A1 publication Critical patent/AR083575A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid

Abstract

Sales de ácido metansulfónico, acido acético, hemioxalato, hemisuccinato. Útil en el tratamiento de cáncer.Reivindicación 1: Un compuesto caracterizado porque es (R)-[5-(2-metoxi-6-metil-piridin-3-il)-2H-pirazol-3-il]-[6-(piperidin-3-iloxi)-pirazin-2-il]-amina de fórmula (1), o una sal del mismo farmacéuticamente aceptable.
ARP110103973A 2010-11-08 2011-10-27 Aminopirazoles para inhibir la proteinquinasa chk1 AR083575A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41113710P 2010-11-08 2010-11-08

Publications (1)

Publication Number Publication Date
AR083575A1 true AR083575A1 (es) 2013-03-06

Family

ID=45044707

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103973A AR083575A1 (es) 2010-11-08 2011-10-27 Aminopirazoles para inhibir la proteinquinasa chk1

Country Status (22)

Country Link
US (1) US9067920B2 (es)
EP (1) EP2638033B1 (es)
JP (1) JP5792316B2 (es)
KR (1) KR101533166B1 (es)
CN (1) CN103180311B (es)
AR (1) AR083575A1 (es)
AU (1) AU2011326230B2 (es)
BR (1) BR112013010009B1 (es)
CA (1) CA2816944C (es)
DK (1) DK2638033T3 (es)
EA (1) EA022096B1 (es)
ES (1) ES2541414T3 (es)
HR (1) HRP20150530T1 (es)
JO (1) JO3145B1 (es)
ME (1) ME02119B (es)
MX (1) MX2013005181A (es)
PL (1) PL2638033T3 (es)
PT (1) PT2638033E (es)
RS (1) RS54012B1 (es)
SI (1) SI2638033T1 (es)
TW (1) TWI501956B (es)
WO (1) WO2012064548A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
EP3411036B1 (en) 2016-02-04 2021-12-29 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
CA3200498A1 (en) 2020-11-30 2022-06-02 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1h-pyrazol-3-amine derivative
WO2023120696A1 (ja) * 2021-12-24 2023-06-29 住友ファーマ株式会社 二環性骨格を有する１ｈ－ピラゾール－３－アミン誘導体
WO2023229032A1 (ja) * 2022-05-27 2023-11-30 住友ファーマ株式会社 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000933A (es) * 2003-07-25 2006-03-30 Pfizer Compuestos de aminopirazol y uso como inhibidores de chk1.
JP2007517843A (ja) * 2004-01-05 2007-07-05 アストラゼネカ アクチボラグ Ｃｈｋ１阻害剤であるチオフェン誘導体
DE602005011279D1 (de) * 2004-06-04 2009-01-08 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
JP2008540391A (ja) * 2005-05-05 2008-11-20 アストラゼネカ アクチボラグ ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
AU2006258101A1 (en) * 2005-06-09 2006-12-21 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1

Also Published As

Publication number Publication date
HRP20150530T1 (hr) 2015-06-19
CA2816944A1 (en) 2012-05-18
PL2638033T3 (pl) 2015-09-30
SI2638033T1 (sl) 2015-05-29
KR101533166B1 (ko) 2015-07-01
BR112013010009B1 (pt) 2021-10-19
ME02119B (me) 2015-10-20
CN103180311A (zh) 2013-06-26
AU2011326230B2 (en) 2015-02-19
AU2011326230A1 (en) 2013-05-09
PT2638033E (pt) 2015-06-01
US20130190262A1 (en) 2013-07-25
JO3145B1 (ar) 2017-09-20
CN103180311B (zh) 2014-08-20
TWI501956B (zh) 2015-10-01
EP2638033A1 (en) 2013-09-18
DK2638033T3 (en) 2015-04-27
EA201390499A1 (ru) 2013-08-30
JP5792316B2 (ja) 2015-10-07
JP2013541586A (ja) 2013-11-14
EA022096B1 (ru) 2015-10-30
TW201305138A (zh) 2013-02-01
MX2013005181A (es) 2013-10-17
EP2638033B1 (en) 2015-04-08
RS54012B1 (en) 2015-10-30
US9067920B2 (en) 2015-06-30
KR20130099146A (ko) 2013-09-05
WO2012064548A1 (en) 2012-05-18
BR112013010009A2 (pt) 2020-09-29
ES2541414T3 (es) 2015-07-20
CA2816944C (en) 2015-12-22

Similar Documents

Publication Publication Date Title
AR083575A1 (es) Aminopirazoles para inhibir la proteinquinasa chk1
CO6382125A2 (es) Inhibidores de proteína quinasa
PE20151412A1 (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
PE20141038A1 (es) Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA201490759A1 (ru) Ингибиторы протеинкиназы
CO6680645A2 (es) Inhibidores de oxadiazol de la producción de leucotrieno
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
ES2691742T3 (es) Tratamiento de cánceres utilizando moduladores de isoformas de PI3 cinasa
ECSP13012964A (es) Tratamientos combinados para neoplasias hematologicas malignas
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
MX2015011245A (es) Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
BR112014002202A2 (pt) macrociclos como inibidores de fator xia
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
EA201391337A1 (ru) Ингибиторы hsp90
CL2016000816A1 (es) Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras.
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
PE20121523A1 (es) Metodo de tratamiento
CO6361991A2 (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.

Legal Events

Date Code Title Description
FG Grant, registration